Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
Dovato 50 mg/300 mg film-coated tablets
dolutegravir/lamivudine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Dovato is a medicine that contains two active ingredients used to treat human immunodeficiency virus (HIV) infection: dolutegravir and lamivudine. Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs), and lamivudine belongs to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Dovato is used to treat HIV in adults and adolescents over 12 years old who weigh at least 40 kg.
Dovato does not cure HIV infection; it keeps the amount of virus in your body at a low level. This helps maintain the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.
Not everyone responds to treatment with Dovato in the same way. Your doctor will monitor the effectiveness of your treatment.
Do not take Dovato
Children
This medicine is not for use in children under 12 years of age, because it has not been studied in these patients.
Other medicines and Dovato
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Don't take Dovato with the following medicine:
Some medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.
Tell your doctor if you are taking any of the medicines in the following list:
St. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.
Tell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check ups.
Pregnancy
If you are pregnant, think you may be pregnant, or if you are planning to have a baby:
Taking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).
If you could get pregnant while taking Dovato:
Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.
Breast-feeding
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Dovato can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Driving and using machines
Dovato can make you dizzy, and have other side effects that make you less alert.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Swallow the tablet with some liquid. Dovato can be taken with or without food.
Use in adolescents
Adolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet once a day.
Antacid medicines
Antacids, to treat indigestion and heartburn, can stop Dovato being absorbed into your body and make it less effective. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it. You can take other acid-lowering medicines like ranitidine and omeprazole at the same time as Dovato.
Supplements or multivitamins containing calcium, iron or magnesium
Supplements or multivitamins containing calcium, iron or magnesium can stop Dovato being absorbed into your body and make it less effective. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it.
If you take more Dovato than you should
If you take too many tablets of Dovato contact your doctor or pharmacist for advice. If possible, show them the Dovato pack.
If you forget to take Dovato
If you miss a dose, take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.
Don’t stop taking Dovato without advice from your doctor
Take Dovato for as long as your doctor recommends. Don’t stop unless your doctor tells you to. Stopping Dovato can affect your health and how future treatment works.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them, so it is very important to talk to your doctor about any changes in your health.
Allergic reactions
Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. This is an uncommon reaction (may affect up to 1 in 100 people) in people taking dolutegravir. If you get any of the following symptoms:
Very common side effects
These may affect more than 1 in 10 people:
Common side effects
These may affect up to 1 in 10 people:
Common side effects that may show up in blood tests are:
Uncommon side effects
These may affect up to 1 in 100 people:
Uncommon side effects that may show up in blood tests are:
Rare side effects
These may affect up to 1 in 1000 people:
Rare side effects that may show up in blood tests are:
Very rare side effects These may affect up to 1 in 10,000 people:
Very rare side effects that may show up in blood tests are:
Other possible side effects
People taking combination therapy for HIV may get other side effects.
Symptoms of infection and inflammation
People with advanced HIV infection or AIDS have weak immune systems, and are more likely to develop serious infections (opportunistic infections). Such infections may have been “silent” and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include fever, plus some of the following:
Joint pain, stiffness and bone problems
Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue are permanently damaged because of reduced blood supply to the bone. People may be more likely to get this condition:
Signs of osteonecrosis include:
Weight, blood lipid and blood glucose effects:
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Contents of the pack and other information What Dovato contains
What Dovato looks like and contents of the pack
Dovato film-coated tablets are oval, biconvex, white tablets debossed with 'SV 137' on one face.
The film-coated tablets are provided in bottles closed with child-resistant closures.
Each bottle contains 30 film-coated tablets.
Multipacks containing 90 film-coated tablets (3 packs of 30 film-coated tablets) are also available. Not all pack sizes may be available in your c ountry
Full name: Dovato 50 mg/300 mg film-coated tablets
- Invented name part: Dovato
- Scientific name part: dolutegravir/lamivudine
- Strength part: 50 mg/300 mg
- Pharmaceutical dose form part: film-coated tablets
Name usage: English (United Kingdom)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: EU/1/19/1370/001
Region:
Marketing authorisation holder: ViiV Healthcare BV
Identifier:
Status: Active (2019-07-01T13:28:17Z)
Package 1 of 1
PMSWI: EU/1/19/1370/001
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 30 Child-resistant closure (Glass)
Containing:
Manufactured Item
Dose form: Film-coated tablet
Unit of presentation: Tablet
Ingredient
Role: Active
Substance: DOLUTEGRAVIR SODIUM
Ingredient
Role: Active
Substance: lamivudine
Ingredient
Role: Excipient
Substance: microcrystalline cellulose
Ingredient
Role: Excipient
Substance: sodium starch glycolate
Ingredient
Role: Excipient
Substance: magnesium stearate
Ingredient
Role: Excipient
Substance: mannitol
Administrable Product (1 of 1)
Dose form: Tablet
Unit of presentation: Tablet
Route of administration:
Ingredient
Role: Active
Substance: DOLUTEGRAVIR SODIUM
Ingredient
Role: Active
Substance: lamivudine
Ingredient
Role: Excipient
Substance: microcrystalline cellulose
Ingredient
Role: Excipient
Substance: sodium starch glycolate
Ingredient
Role: Excipient
Substance: magnesium stearate
Ingredient
Role: Excipient
Substance: mannitol